Estimands and Their Role in Clinical Trials

被引：44

作者：

Akacha, Mouna ^{[1
]}

Bretz, Frank ^{[1
,2
]}

Ohlssen, David ^{[3
]}

Rosenkranz, Gerd ^{[2
]}

Schmidli, Heinz ^{[1
]}

机构：

[1] Novartis Pharma AG, Stat Methodol & Consulting, CH-4002 Basel, Switzerland

[2] Med Univ Vienna, Ctr Med Stat Informat & Intelligent Syst, Vienna, Austria

[3] Novartis Pharmaceut, Stat Methodol & Consulting, E Hanover, NJ USA

来源：

STATISTICS IN BIOPHARMACEUTICAL RESEARCH | 2017年 / 9卷 / 03期

关键词：

Estimand; ICH E9 guideline; Missing data; Sensitivity analysis; MISSING DATA; PERSPECTIVE; IMPUTATION;

D O I：

10.1080/19466315.2017.1302358

中图分类号：

Q [生物科学];

学科分类号：

07 ; 0710 ; 09 ;

摘要：

The National Research Council (NRC) highlighted the need to more clearly distinguish between the target of estimation (estimand) and the method of estimation (estimator) in clinical trials. While the NRC report on The Prevention and Treatment of Missing Data in Clinical Trials focuses on issues arising due to missing data, a framework to coherently align trial objectives and corresponding estimands is valuable in a broader sense. The International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use (ICH) has reinforced this by tasking a working group to develop an addendum to the ICH-E9 guideline Statistical Principles for Clinical Trials. In this article, we motivate the need for change, propose a structured framework to bridge trial objectives with proper inference tools, and discuss how it may impact the role of statisticians involved in clinical trial design and analysis.

引用

页码：268 / 271

页数：4

共 20 条

[1] Estimands in clinical trials - broadening the perspective [J].

Akach, Mouna ;

Bretz, Frank ;

Ruberg, Stephen .

STATISTICS IN MEDICINE, 2017, 36 (01) :5-19

[2]

[Anonymous], 2014, E9R1 INT C HARM TECH

[3]

FDA, 2011, BRIEF DOC

[4] Randomized Trials Analyzed as Observational Studies [J].

Hernan, Miguel A. ;

Hernandez-Diaz, Sonia ;

Robins, James M. .

ANNALS OF INTERNAL MEDICINE, 2013, 159 (08) :560-+

[5] Choice of estimand and analysis methods in diabetes trials with rescue medication [J].

Holzhauer, Bjoern ;

Akacha, Mouna ;

Bermann, Georgina .

PHARMACEUTICAL STATISTICS, 2015, 14 (06) :433-447

[6]

International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use, 1998, ICH HARM TRIP GUID E

[7] A regulatory perspective on missing data in the aftermath of the NRC report [J].

LaVange, Lisa M. ;

Permutt, Thomas .

STATISTICS IN MEDICINE, 2016, 35 (17) :2853-2864

[8] Choosing Appropriate Estimands in Clinical Trials [J].

Leuchs, Ann-Kristin ;

Zinserling, Joerg ;

Brandt, Andreas ;

Wirtz, Dorothee ;

Benda, Norbert .

THERAPEUTIC INNOVATION & REGULATORY SCIENCE, 2015, 49 (04) :584-592

[9] Intention-to-treat analysis with treatment discontinuation and missing data in clinical trials [J].

Little, Roderick ;

Kang, Shan .

STATISTICS IN MEDICINE, 2015, 34 (16) :2381-2390

[10] Control-Based Imputation and Delta-Adjustment Stress Test for Missing Data Analysis in Longitudinal Clinical Trials [J].

Liu, G. Frank ;

Pang, Lei .

STATISTICS IN BIOPHARMACEUTICAL RESEARCH, 2017, 9 (02) :186-194

← 1 2 →